Alpha Cognition Inc (TSE:ACOG) has released an update.
Alpha Cognition Inc. has announced the FDA approval of ZUNVEYL, a novel oral therapy for treating Alzheimer’s disease, designed to improve tolerability and long-term cognitive function. ZUNVEYL distinguishes itself by targeting the elimination of drug absorption in the GI tract, potentially reducing the side effects that often cause patients to discontinue treatment. The therapy also offers benefits in daily living activities for the nearly 7 million Americans affected by Alzheimer’s.
For further insights into TSE:ACOG stock, check out TipRanks’ Stock Analysis page.
